Condition: C3G · Sponsor: Novartis Pharmaceuticals
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Childrens Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Nicklaus Childrens Hospital | Miami, Florida, United States | Recruiting |
| Georgia Nephrology Research Inst | Lawrenceville, Georgia, United States | Completed |
| IN University School of Med | Indianapolis, Indiana, United States | Withdrawn |
| University of Iowa Health Care | Iowa City, Iowa, United States | Recruiting |
| University of Iowa Health Care | Iowa City, Iowa, United States | Recruiting |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Withdrawn |
| Brigham and Womens Hosp Harvard Med School | Boston, Massachusetts, United States | Withdrawn |
| Hackensack Uni Medical Center | Hackensack, New Jersey, United States | Withdrawn |
| Albany Medical Center | Albany, New York, United States | Withdrawn |
| Col Uni Med Center New York Presby | New York, New York, United States | Completed |
| Baylor Scott and White Research | Temple, Texas, United States | Withdrawn |
+ 75 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04817618